Back
Recursion Pharmaceuticals 10K Form
Sell
37
RXRX
Recursion Pharmaceuticals
Last Price:
$7.24
Seasonality Move:
-18.3%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RXRX News And Ratings
See the #1 stock for the next 7 days that we like better than RXRX
RXRX Financial Statistics
Sales & Book Value
| Annual Sales: | $43.9M |
|---|---|
| Cash Flow: | $-63.8M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.83 |
| Price / Book: | 3.82 |
Profitability
| EPS (TTM): | -1.55000 |
|---|---|
| Net Income (TTM): | $-377.8M |
| Gross Margin: | $1.3M |
| Return on Equity: | -78.32% |
| Return on Assets: | -56.47% |
Recursion Pharmaceuticals Earnings Forecast
Key Recursion Pharmaceuticals Financial Ratios
-
The Gross Profit Margin over the past 4 years for RXRX is 2.94%.
-
The Selling, General & Administrative Expenses for RXRX have been equal to 252.58% of Gross Profit Margin.
-
The Research & Development expenses have been 549.79% of Revenue.
-
The Interest Expense is -0.03% of Operating Income.
-
The Net Earning history of RXRX is -747.71% of Total Revenues.
-
Per Share Earnings over the last 5 years have been positive in 1 years.
Recursion Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RXRX |
| Website: | recursion.com |
Debt
| Debt-to-Equity Ratio: | 0.05 |
|---|---|
| Current Ratio: | 4.35 |
| Quick Ratio: | 3.95 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RXRX Technical Analysis vs Fundamental Analysis
Sell
37
Recursion Pharmaceuticals (RXRX)
is a Sell
Is Recursion Pharmaceuticals a Buy or a Sell?
-
Recursion Pharmaceuticals stock is rated a SellThe current Recursion Pharmaceuticals [RXRX] share price is $6.99. The Score for RXRX is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.